---
title: "Xarelto (rivaroxaban), all indications: Safety questions"
description: "Safety questions on Xarelto (rivaroxaban) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Monitoring, Warnings, Bleeding management, and Side effects. Questions: Does Xarelto need INR or coagulation monitoring? What is the Xarelto boxed warning about stopping early and spinal hematoma? Does Xarelto increase the risk of bleeding? Is there a reversal agent for Xarelto? 6 further questions follow. 10 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/xarelto/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xarelto (rivaroxaban), all indications: Safety questions

Manufacturer: Janssen Pharmaceuticals, Inc.  
Prescribing information: [Xarelto](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf)  
Indication pages: [Nonvalvular atrial fibrillation](https://www.evicenter.com/medical-information/xarelto--nonvalvular-atrial-fibrillation)

## Monitoring

<a id="xarelto-monitoring"></a>

### Does Xarelto need INR or coagulation monitoring?

> “Monitoring for anticoagulation effect of rivaroxaban using anti-FXa activity or a 
> clotting test is not recommended.”

Source: [XARELTO: Prescribing information, page 12, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=12)

> “XARELTO® requires no routine coagulation monitoring with treatment due to predictable PK/PD.<sup>2,3,15,20,21</sup> The INR is not recommended because it is only calibrated and validated for VKAs.<sup>35</sup>”

Source: [XARELTO: Frequently Asked Questions (FAQs), captured 2026-11-13](https://www.xareltohcp.com/faqs/#general-questions:~:text=XARELTO%C2%AE%20requires%20no%20routine%20coagulation,only%20calibrated%20and%20validated%20for)

This passage is in a collapsed section of the page; select: Do patients taking XARELTO® need to have their coagulation levels monitored?

Note: The first passage is from the Prescribing Information and the second is the manufacturer's FAQ answer. For atrial fibrillation, the Prescribing Information separately advises periodic assessment of renal function (see the kidney dosing question).

## Warnings

<a id="xarelto-boxed-warning"></a>

### What is the Xarelto boxed warning about stopping early and spinal hematoma?

> “WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES 
> THE RISK OF THROMBOTIC EVENTS,  
> (B) SPINAL/EPIDURAL HEMATOMA
> A.	 Premature discontinuation of XARELTO increases the risk of thrombotic 
> events
> Premature discontinuation of any oral anticoagulant, including XARELTO, 
> increases the risk of thrombotic events. If anticoagulation with XARELTO is 
> discontinued for a reason other than pathological bleeding or completion of 
> a course of therapy, consider coverage with another anticoagulant [see 
> Dosage and Administration (2.3, 2.4), Warnings and Precautions (5.1), and 
> Clinical Studies (14.1)].
> B.	 Spinal/epidural hematoma
> Epidural or spinal hematomas have occurred in patients treated with 
> XARELTO who are receiving neuraxial anesthesia or undergoing spinal 
> puncture. These hematomas may result in long-term or permanent paralysis. 
> Consider these risks when scheduling patients for spinal procedures. 
> Factors that can increase the risk of developing epidural or spinal 
> hematomas in these patients include:
> •	 use of indwelling epidural catheters
> •	 concomitant use of other drugs that affect hemostasis, such as non-
> steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other 
> anticoagulants
> •	 a history of traumatic or repeated epidural or spinal punctures
> •	 a history of spinal deformity or spinal surgery
> •	 optimal timing between the administration of XARELTO and neuraxial 
> procedures is not known
> [see Warnings and Precautions (5.2, 5.3) and Adverse Reactions (6.2)].
> Monitor patients frequently for signs and symptoms of neurological 
> impairment. If neurological compromise is noted, urgent treatment is 
> necessary [see Warnings and Precautions (5.3)].”

Source: [XARELTO: Prescribing information, page 3, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=3)

<a id="xarelto-bleeding-risk"></a>

### Does Xarelto increase the risk of bleeding?

> “XARELTO increases the risk of bleeding, including in any organ, and can cause 
> serious or fatal bleeding. In deciding whether to prescribe XARELTO to patients at 
> increased risk of bleeding, the risk of thrombotic events should be weighed 
> against the risk of bleeding.
> Promptly evaluate any signs or symptoms of blood loss and consider the need for 
> blood replacement. Discontinue XARELTO in patients with active pathological 
> hemorrhage. The terminal elimination half-life of rivaroxaban is 5 to 9 hours in 
> healthy subjects aged 20 to 45 years.
> Concomitant use of other drugs that impair hemostasis increases the risk of 
> bleeding. These include aspirin, P2Y12 platelet inhibitors, dual antiplatelet 
> therapy, other antithrombotic agents, fibrinolytic therapy, non-steroidal anti-
> inflammatory drugs (NSAIDs) [see Drug Interactions (7.4)], selective serotonin 
> reuptake inhibitors, and serotonin norepinephrine reuptake inhibitors.”

Source: [XARELTO: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=6)

<a id="xarelto-contraindications"></a>

### Who should not take Xarelto (contraindications)?

> “XARELTO is contraindicated in patients with:
> •	 active pathological bleeding [see Warnings and Precautions (5.2)]
> •	 severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions) 
> [see Adverse Reactions (6.2)]”

Source: [XARELTO: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=5)

<a id="xarelto-spinal-epidural"></a>

### Can patients taking Xarelto have spinal or epidural anesthesia?

> “An indwelling epidural or intrathecal catheter should not be removed before at 
> least 2 half-lives have elapsed (i.e., 18 hours in young patients aged 20 to 45 years 
> and 26 hours in elderly patients aged 60 to 76 years), after the last administration of 
> XARELTO [see Clinical Pharmacology (12.3)]. The next XARELTO dose should not be 
> administered earlier than 6  hours after the removal of the catheter. If traumatic 
> puncture occurs, delay the administration of XARELTO for 24 hours.”

Source: [XARELTO: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=6)

> “Placement or removal of an epidural catheter or lumbar puncture is best 
> performed when the anticoagulant effect of XARELTO is low; however, the exact 
> timing to reach a sufficiently low anticoagulant effect in each patient is not known.”

Source: [XARELTO: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=6)

<a id="xarelto-heart-valves"></a>

### Can Xarelto be used with a prosthetic heart valve or after TAVR?

> “On the basis of the GALILEO study, use of XARELTO is not recommended in 
> patients who have had transcatheter aortic valve replacement (TAVR) because 
> patients randomized to XARELTO experienced higher rates of death and bleeding 
> compared to those randomized to an anti-platelet regimen. The safety and 
> efficacy of XARELTO have not been studied in patients with other prosthetic 
> heart valves or other valve procedures. Use of XARELTO is not recommended in 
> patients with prosthetic heart valves.”

Source: [XARELTO: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=6)

<a id="xarelto-antiphospholipid"></a>

### Is Xarelto recommended in antiphospholipid syndrome?

> “Direct-acting oral anticoagulants (DOACs), including XARELTO, are not 
> recommended for use in patients with triple-positive antiphospholipid syndrome 
> (APS). For patients with APS (especially those who are triple positive [positive for 
> lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), 
> treatment with DOACs has been associated with increased rates of recurrent 
> thrombotic events compared with vitamin K antagonist therapy.”

Source: [XARELTO: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=7)

## Bleeding management

<a id="xarelto-reversal"></a>

### Is there a reversal agent for Xarelto?

> “A specific agent to reverse the anti-factor Xa activity of rivaroxaban is not available. 
> Because of high plasma protein binding, rivaroxaban is not dialyzable [see Clinical 
> Pharmacology (12.3)]. Protamine sulfate and vitamin K are not expected to affect 
> the anticoagulant activity of rivaroxaban. Use of procoagulant reversal agents, such 
> as prothrombin complex concentrate (PCC), activated prothrombin complex 
> concentrate or recombinant factor VIIa, may be considered but has not been 
> evaluated in clinical efficacy and safety studies. Monitoring for the anticoagulation 
> effect of rivaroxaban using a clotting test (PT, INR or aPTT) or anti-factor Xa (FXa) 
> activity is not recommended.”

Source: [XARELTO: Prescribing information, page 6, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=6)

> “A specific agent to reverse the anti-factor Xa activity of XARELTO® is not available.”

Source: [XARELTO: Treatment Considerations, captured 2026-11-13](https://www.xareltohcp.com/treatment-considerations/#:~:text=A%20specific%20agent%20to%20reverse,of%20XARELTO%C2%AE%20is%20not%20available.)

Note: The Prescribing Information revised 03/2026 and the treatment considerations page state that a specific reversal agent is not available. The FAQ page of the Xarelto HCP site, as captured on November 13, 2026, states in its expanded answer to the reversal question that "An agent to reverse the anti-factor Xa activity of rivaroxaban is available", while the Important Safety Information on the same page states that one is not available; the Prescribing Information is quoted here.

## Side effects

<a id="xarelto-postmarketing"></a>

### What other side effects have been reported with Xarelto after approval?

> “The following adverse reactions have been identified during post-approval use of 
> XARELTO. Because these reactions are reported voluntarily from a population of 
> uncertain size, it is not always possible to reliably estimate their frequency or 
> establish a causal relationship to drug exposure.
> Blood and lymphatic system disorders: agranulocytosis, thrombocytopenia
> Hepatobiliary disorders: jaundice, cholestasis, hepatitis (including hepatocellular injury)
> Immune system disorders: hypersensitivity, anaphylactic reaction, anaphylactic 
> shock, angioedema
> Nervous system disorders: hemiparesis
> Renal disorders: Anticoagulant-related nephropathy
> Respiratory, thoracic and mediastinal disorders: Eosinophilic pneumonia
> Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome, drug 
> reaction with eosinophilia and systemic symptoms (DRESS)
> Injury, poisoning and procedural complications: Atraumatic splenic rupture”

Source: [XARELTO: Prescribing information, page 10, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=10)

## Safety

<a id="xarelto-overdose"></a>

### What should be done after a Xarelto overdose?

> “Overdose of XARELTO may lead to hemorrhage. Discontinue XARELTO and initiate 
> appropriate therapy if bleeding complications associated with overdosage occur. 
> Rivaroxaban systemic exposure is not further increased at single doses >50 mg 
> due to limited absorption. The use of activated charcoal to reduce absorption in 
> case of XARELTO overdose may be considered. Due to the high plasma protein 
> binding, rivaroxaban is not dialyzable [see Warnings and Precautions (5.2) and 
> Clinical Pharmacology (12.3)]. Partial reversal of laboratory anticoagulation 
> parameters may be achieved with use of plasma products. A specific agent to 
> reverse the anti-factor Xa activity of rivaroxaban is not available.”

Source: [XARELTO: Prescribing information, page 12, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf#page=12)

## Related pages
- [Medical information: Xarelto (rivaroxaban): All indications](https://www.evicenter.com/medical-information/xarelto)
- [Indication](https://www.evicenter.com/medical-information/xarelto/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xarelto/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/xarelto/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xarelto/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xarelto/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/xarelto/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/xarelto/access-and-coverage)
